Table 1.
Baseline characteristics of subjects in a pilot study of the effects of low-dose growth hormone in HIV-infected men with fat accumulation.
| Patient | Age, years | BMI | Waist circumference, cm | Waist-to-hip ratio | CD4+ cell count, cells/μL | Antiretroviral regimena |
|---|---|---|---|---|---|---|
| 1 | 48 | 25.7 | 93.0 | 0.98 | 412 | D4T, 3TC, IDV, RTV |
| 2 | 49 | 23.8 | 92.5 | 0.98 | 449 | RTV, AMP, EFV |
| 3 | 46 | 28.0 | 94.5 | 1.00 | 527 | DDI, 3TC, NEV |
| 4 | 58 | 26.1 | 102.5 | 1.04 | 1433 | 3TC, IDV, EFV |
| 5 | 41 | 29.8 | 102.2 | 1.02 | 464 | AZT, 3TC, RTV/LPV |
NOTE. All patients had experienced both enlargement of the dorsocervical fat pad and an increase in abdominal girth; in addition, patients 1, 2, and 4 also complained of loss of fat in the face and extremities. AMP, amprenavir; AZT, zidovudine; BMI, body mass index (calculated as weight [in kg] divided by height [in m] squared); DDI, didanosine; D4T, stavudine; EFV, efavirenz; IDV, indinavir; LPV, lopinavir; NEV, nevirapine; RTV, ritonavir; 3TC, lamivudine.
All patients received the same antiretroviral regimen for ≥6 months prior to the study, with the exception of patient 2, who underwent a transient (<1 month) substitution of delavirdine for RTV 2 months before the study but then returned to his stable regimen of RTV, AMP, and EFV, which he had been receiving for the previous year. Patient 2 was also receiving human chorionic gonadotropin (for Kaposi sarcoma in remission) and atorvastatin, and patient 3 was receiving testosterone (replacement), gemfibrozil, and niacin during the study.